zhangying feng

Dr. zhangying feng

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in International Immunopharmacology
Verified
Journal Article
Closed access
CCCheng Cui
Cheng Cui
HFHelin Feng
Helin Feng
XSXinli Shi
Xinli Shi
YWYazhuo Wang
Yazhuo Wang
ZFzhangying feng
zhangying feng
HTHui Tong
Hui Tong

21 October 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
SCShanshan Chen
Shanshan Chen
YLYu Liang
Yu Liang
ZFzhangying feng
zhangying feng
MWMingxia Wang
Mingxia Wang
Background: Although the dual anti-HER2 therapy, namely, pertuzumab plus trastuzumab and docetaxel, has shown promising results in HER2+ breast cancer patients, whether the dose, efficacy and safety of this treatment differs from those of other pertuzumab-based dual anti-HER2 therapies remain controversial. This systematic review evaluates the efficacy and safety of H (trastuzumab or trastuzumab emtansine ± chemotherapy) + P (pertuzumab) compared with those of H in HER2+ breast cancer patients.Methods: A comprehensive search was performed to identify eligible studies comparing the efficacy and safety of H + P versus H. The pathologic complete response (pCR), median progression-free survival (PFS) and overall survival (OS) were the primary outcomes, and safety was the secondary outcome. A subgroup analysis of pCR according to hormone receptor (HR) status was performed. All analyses were conducted using STATA 11.0.Results: Twenty-six studies (9872 patients) were identified. In the neoadjuvant setting, H + P significantly improved the pCR [odds ratio (OR) = 1.33; 95% confidence interval (CI), 1.08–1.63;p = 0.006]. In the metastatic setting, H + P significantly improved PFS [hazard ratios (HRs) = 0.75; 95% CI, 0.68–0.84;p < 0.001]. There was a trend towards better OS but that it did not reach statistical significance (HRs = 0.81; 95% CI, 0.64–1.03;p = 0.082). A subgroup analysis revealed that the HER2+/HR- patients who received H + P showed the highest increase in the pCR. Rash, diarrhea, epistaxis, mucosal inflammation, and anemia were significantly more frequently observed with H + P than with H, whereas myalgia was less frequent (OR = 0.91; 95% CI, 0.82–1.01;p = 0.072), and no significant difference in cardiac toxicity was observed between these therapies (OR = 1.26; 95% CI, 0.81–1.95;P = 0.309).Conclusions: Our study confirms that H + P is superior to H in the (neo)adjuvant treatment of HER2+ breast cancer, and increase the risk of acceptable and tolerable toxicity (rash, diarrhea, epistaxis, mucosal inflammation, and anemia).Trial registration: A systematic review protocol was registered with PROSPERO (identification number:CRD42018110415).

29 December 2012 in Endocrine
Verified
Journal Article
Closed access
PDF file
HFHelin Feng
Helin Feng
LZLihua Zheng
Lihua Zheng
ZFzhangying feng
zhangying feng
YZYaheng Zhao
Yaheng Zhao
NZNing Zhang
Ning Zhang

1 July 2013 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JSJialin Sun
Jialin Sun
LZLi Zhang
Li Zhang
Junke SongJunke Song
Junke Song
STShuo Tian
Shuo Tian
CHChao Huang
Chao Huang
GDGuanhua Du
Guanhua Du

26 July 2022 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
XGXiao-Nan Gao
Xiao-Nan Gao
XNXu-Yang Nie
Xu-Yang Nie
JGJing-Lin Gao
Jing-Lin Gao
THTian-Fang Heng
Tian-Fang Heng
YZYu-Qi Zhang
Yu-Qi Zhang
LJLi Jia
Li Jia
Purpose: This study aimed to characterize the pharmacokinetics of nalbuphine in patients undergoing general anesthesia with varying degrees of liver dysfunction. Patients and Methods: Twenty-four patients were enrolled and divided into three cohorts based on liver function: normal liver function (n = 13), mild liver dysfunction (n = 5), and moderate/severe liver dysfunction (n = 6). During the induction of anesthesia, they received 15 mg of nalbuphine intravenously. Venous blood samples were collected from each patient. The plasma concentration of nalbuphine was determined using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). The pharmacokinetic parameters of nalbuphine were calculated by non-compartmental analysis (NCA) using Phoenix WinNonlin software. Results: Compared with the normal liver function group, the plasma elimination half-life (T1/2) of nalbuphine was increased by approximately 33% in the moderate/severe liver dysfunction group (2.66 h vs 3.54 h, P< 0.05), and the volume of distribution (Vd) increased by approximately 85% (100.08 L vs 184.95 L, P< 0.05). Multivariate analysis revealed that weight and platelet were associated with clearance (CL); total bilirubin as an independent factor was associated with T1/2, and weight associated with area under the curve (AUC(0→∞)) independently. Conclusion: The T1/2, mean residence time, and Vd of nalbuphine in patients with moderate/severe liver dysfunction were prolonged or increased significantly compared with those in the normal liver function group. These data suggest that it may need to be used with caution when nalbuphine is administered to patients with moderate or severe liver dysfunction.

1 May 2015 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
Junke SongJunke Song
Junke Song
WZWen Zhang
Wen Zhang
JSJialin Sun
Jialin Sun
XXXiaona Xu
Xiaona Xu
XZXue Zhang
Xue Zhang
GDGuanhua Du
Guanhua Du
A sensitive, specific and rapid LC-MS method was developed and validated for the determination of salvianolic acid D (SalD) in rat plasma. This method used a single quadrupole mass spectrometer with an electrospray ionization (ESI) source. A single ion monitoring scanning (SIM) mode was employed. It showed good linearity over the concentration range from 3.3 to 666.7 ng/mL for the determination of SalD. The R.S.D.% of intra-day and inter-day precision values were no more than 7.69%, and the accuracy was within 91%-104% at all quality control levels. This LC-MS method was applied to the pharmacokinetic study of SalD in rats. A two-compartmental model analysis was employed. The plasma concentrations at 2 min (C 2min) were 5756.06±719.61, 11,073.01±1783.46 and 21,077.58±5581.97 μg/L for 0.25, 0.5 and 1 mg/kg intravenous injection, respectively. The peak plasma concentration (C max) was 333.08±61.21 μg/L for 4 mg/kg oral administration. The area under curve (AUC0-t ) was 14,384.379±8443.184, 22,813.369±11,860.823, 46,406.122±27,592.645 and 8201.740±4711.961 μg/L·h for intravenous injection (0.25, 0.5 and 1 mg/kg) and oral administration (4 mg/kg), respectively. The bioavailability of SalD was calculated to be 4.159%±0.517%.